Article: An update on targeting Hippo-YAP signaling in liver cancer

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleAn update on targeting Hippo-YAP signaling in liver cancer
AuthorsLiu, AM1
Xu, Z2
Luk, JM1 2 3
Issue Date2012
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett
CitationExpert Opinion On Therapeutic Targets, 2012, v. 16 n. 3, p. 243-247 [How to Cite?]
DOI: http://dx.doi.org/10.1517/14728222.2012.662958
AbstractHepatocellular carcinoma (HCC) is an aggressive malignancy with approximately half a million cases diagnosed each year. Although strategies in surgical interventions have been investigated and applied, the prognosis is still poor. Novel chemotherapy for advanced stage HCC patients is still greatly in need. HippoYes-associated protein (YAP) signaling pathway controls organ size by regulating both cell proliferation and apoptosis during normal development. The pathway also has a prominent role in suppressing tumor growth, with the most evident contribution in HCC. In recent years, regulators of this pathway have gradually been revealed, providing new information for understanding this complex yet important growth-control signaling. This knowledge provides a basis for rational design of therapeutics against cancer that depends upon HippoYAP signaling for growth. © 2012 Informa UK, Ltd.
ISSN1472-8222
2011 Impact Factor: 3.716
2011 SCImago Journal Rankings: 0.370
DOIhttp://dx.doi.org/10.1517/14728222.2012.662958
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorLiu, AM
dc.contributor.authorXu, Z
dc.contributor.authorLuk, JM
dc.date.accessioned2012-10-30T06:26:40Z
dc.date.available2012-10-30T06:26:40Z
dc.date.issued2012
dc.description.abstractHepatocellular carcinoma (HCC) is an aggressive malignancy with approximately half a million cases diagnosed each year. Although strategies in surgical interventions have been investigated and applied, the prognosis is still poor. Novel chemotherapy for advanced stage HCC patients is still greatly in need. HippoYes-associated protein (YAP) signaling pathway controls organ size by regulating both cell proliferation and apoptosis during normal development. The pathway also has a prominent role in suppressing tumor growth, with the most evident contribution in HCC. In recent years, regulators of this pathway have gradually been revealed, providing new information for understanding this complex yet important growth-control signaling. This knowledge provides a basis for rational design of therapeutics against cancer that depends upon HippoYAP signaling for growth. © 2012 Informa UK, Ltd.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationExpert Opinion On Therapeutic Targets, 2012, v. 16 n. 3, p. 243-247 [How to Cite?]
DOI: http://dx.doi.org/10.1517/14728222.2012.662958
dc.identifier.doihttp://dx.doi.org/10.1517/14728222.2012.662958
dc.identifier.epage247
dc.identifier.issn1472-8222
2011 Impact Factor: 3.716
2011 SCImago Journal Rankings: 0.370
dc.identifier.issue3
dc.identifier.pmid22335485
dc.identifier.scopuseid_2-s2.0-84863298936
dc.identifier.spage243
dc.identifier.urihttp://hdl.handle.net/10722/173030
dc.identifier.volume16
dc.languageeng
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett
dc.publisher.placeUnited Kingdom
dc.relation.ispartofExpert Opinion on Therapeutic Targets
dc.relation.referencesReferences in Scopus
dc.subject.meshAnimals
dc.subject.meshCarcinoma, Hepatocellular - Metabolism
dc.subject.meshHumans
dc.subject.meshIntracellular Signaling Peptides And Proteins - Metabolism
dc.subject.meshLiver Neoplasms - Metabolism
dc.subject.meshNuclear Proteins - Metabolism
dc.subject.meshProtein-Serine-Threonine Kinases - Metabolism
dc.subject.meshSignal Transduction
dc.subject.meshTranscription Factors - Metabolism
dc.titleAn update on targeting Hippo-YAP signaling in liver cancer
dc.typeArticle
Author Affiliations
  1. Yong Loo Lin School of Medicine
  2. Nanjing Medical University
  3. null